Muscular dystrophy, which affects approximately 250,000 people in the U.S., occurs when damaged muscle tissue is replaced with fibrous, fatty or bony tissue and loses function. For years, scientists have searched for a way to successfully treat the most common form of the disease, Duchenne Muscular Dystrophy (DMD), which primarily affects boys. Now, a team of University of Missouri researchers have successfully treated dogs with DMD and say that human clinical trials are being planned in the next few years.
“This is the most common muscle disease in boys, and there is currently no effective therapy,” saidDongsheng Duan, the study leader and the Margaret Proctor Mulligan Professor in Medical Research at the MU School of Medicine. “This discovery took our research team more than 10 years, but we believe we are on the cusp of having a treatment for the disease.”
Patients with Duchenne muscular dystrophy have a gene mutation that disrupts the production of a protein known as “dystrophin.” Absence of dystrophin starts a chain reaction that eventually leads to muscle cell degeneration and death. Affected boys lose their ability to walk and breathe as they get older. This places significant limitations on individuals afflicted with the disease. Dystrophin also is one of the largest genes in the human body.
“Due to its size, it is impossible to deliver the entire gene with a gene therapy vector, which is the vehicle that carries the therapeutic gene to the correct site in the body,” Duan said. “Through previous research, we were able to develop a miniature version of this gene called a microgene. This minimized dystrophin protected all muscles in the body of diseased mice.”
However, it took the team more than 10 years to develop a strategy that can safely send the micro-dystrophin to every muscle in a dog that is afflicted by the disease. The dog has a body size similar to that of an affected boy. Success in the dog will set the foundation for human tests.
In this latest study, the MU team demonstrated for the first time that a common virus can deliver the microgene to all muscles in the body of a diseased dog. The dogs were injected with the virus when they were two to three months old and just starting to show signs of DMD. The dogs are now six to seven months old and continue to develop normally.
“The virus we are using is one of the most common viruses; it is also a virus that produces no symptoms in the human body, making this a safe way to spread the dystrophin gene throughout the body,” Duan said. “These dogs develop DMD naturally in a similar manner as humans. It’s important to treat DMD early before the disease does a lot of damage as this therapy has the greatest impact at the early stages in life.”
The Latest on: Muscular Dystrophy
via Google News
The Latest on: Muscular Dystrophy
- Byron Fire Department begins 'Fill the Boot' campaign to raise money for muscular dystrophyon July 5, 2019 at 9:16 pm
BYRON, Ga. — The Byron Fire Department began their annual "Fill the Boot" campaign Friday. Every Friday afternoon in July will be devoted to collecting money towards a good cause. Battling hot ... […]
- Staten Islander with muscular dystrophy inspires with walk from St. George to the S.I. Mallon July 5, 2019 at 3:33 pm
STATEN ISLAND, N.Y.-- There is one word that 22-year-old Eric Sogomonian says will never utter, even under the worst circumstances. That word is “can’t.” Sogomonian, who prefers to be called Eric Sogo ... […]
- US Duchenne Muscular Dystrophy Market and Competitive Landscape - 2019 - ResearchAndMarkets.comon July 2, 2019 at 2:42 am
DUBLIN--(Business Wire)--The "US Duchenne Muscular Dystrophy Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering. The latest research, US Duchenne ... […]
- Tornado encourages Pennsylvania family fighting muscular dystrophyon July 1, 2019 at 11:46 am
Tornado encourages Pennsylvania family in expensive fight with son's destructive disease A tornado that ripped through their orchard gave the Andrews family the strength to ask for help in their son's ... […]
- Pfizer gene therapy has efficacy in Duchenne muscular dystrophy, but data raise questionson July 1, 2019 at 10:03 am
Data presented at a medical conference last Friday provided a peek at the potential efficacy of a gene therapy under development by Pfizer for a rare genetic disorder that causes muscle degeneration. ... […]
- Pfizer’s Duchenne Muscular Dystrophy Pain Could Make Sarepta the DMD Kingon June 29, 2019 at 5:50 am
Pfizer Inc. (NYSE: PFE) has released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy (DMD). While these results did not necessarily live up to ... […]
- Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD)on June 28, 2019 at 7:47 am
Pfizer Inc. (PFE) will present initial Phase 1b clinical data on PF-06939926, an investigational gene therapy to potentially treat Duchenne muscular dystrophy (DMD) at the 25th Annual Parent ... […]
- Paul McCartney urges Texas A&M to end golden retriever experiments in muscular dystrophy researchon June 26, 2019 at 1:53 pm
AUSTIN — Legendary rock icon Paul McCartney is using his superstar status to put pressure on Texas A&M to close a research facility that uses golden retrievers for muscular dystrophy medical testing. ... […]
- Parent Project Muscular Dystrophy Hosts 25th Annual Conference in Orlandoon June 26, 2019 at 9:30 am
HACKENSACK, N.J., June 26, 2019 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), will mark their 25 ... […]
- Targeting a therapeutic LIF transgene to muscle via the immune system ameliorates muscular dystrophyon June 26, 2019 at 2:36 am
Many potentially therapeutic molecules have been identified for treating Duchenne muscular dystrophy. However, targeting those molecules only to sites of active pathology is an obstacle to their ... […]
via Bing News